Skip to main content

Advertisement

SpringerLink
Log in

18F-FDG PET/CT role in Burkitt lymphoma

  • Mini - Review
  • Published:
Clinical and Translational Imaging Aims and scope Submit manuscript

Abstract

Purpose

Burkitt lymphoma (BL) is an aggressive non-Hodgkin lymphoma with unclear metabolic behavior at fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and no shared criteria in treatment evaluation and prediction of outcome. The aim of this review was to analyze the published data about the role of 18F-FDG PET/CT in patients affected by BL.

Methods

A comprehensive computer literature search of the Scopus, PubMed/MEDLINE, Embase and Cochrane library databases was conducted including articles up to November 2019 to find relevant published papers about BL and 18F-FDG PET/CT, focus on the possible role on staging, treatment response and prognostication.

Results

Our computer literature search revealed 88 articles. On reviewing the titles and abstracts, 75 articles were excluded because the reported data were not within the field of interest of this review. Finally, 13 articles were selected and retrieved in full-text version. From the analyses of these, the following main findings have been found: (1) BL can considered an 18F-FDG-avid lymphoma with an optimal diagnostic accuracy of 18F-FDG PET/CT; (2) 18F-FDG PET/CT seems to be better than conventional imaging in studying BL and detecting sites of involvement; (3) despite initial positive evidences, the role of PET treatment response evaluation and prognostication is yet unclear due to the low patients evaluated and controversial results.

Conclusions

BL is an 18F-FDG-avid lymphoma histotype and 18F-FDG PET/CT is the best imaging tool to stage patients affected by BL. Preliminary findings about the usefulness of FDG PET/CT features in the evaluation of treatment response and prognosis are available without strong evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bishop PC, Rao VK, Wilson WH (2000) Burkitt’s lymphoma: molecular pathogenesis and treatment. Cancer Investig 18:574–583

    Article  CAS  Google Scholar 

  2. Molineux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G et al (2012) Burkitt’s lymphoma. Lancet 379:1234–1244

    Article  Google Scholar 

  3. Wästerlid T, Brown PN, Hagberg O, Hagberg H, Pedersen LM, D’Amore F et al (2013) Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic lymphoma group. Ann Oncol 24:1879–1886

    Article  Google Scholar 

  4. Sandlund JT (2012) Burkitt lymphoma: staging and response evaluation. Br J Hematol 156:761–765

    Article  CAS  Google Scholar 

  5. Just PA, Fieschi C, Baillet G, Galicier L, Oksenhendler E, Moretti JL (2008) 18F-fluorodeoxyglucose positron emission tomography/computed tomography in AIDS-related Burkitt lymphoma. AIDS Patient Care STDS 22:695–700

    Article  Google Scholar 

  6. Zeng W, Lechowicz MJ, Winton E, Cho SM, Galt JR, Halkar R (2009) Spectrum of FDG PET/CT findings in Burkitt lymphoma. Clin Nucl Med 4:355–358

    Article  Google Scholar 

  7. Weiler-Sage M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I et al (2010) 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 51:25–30

    Article  Google Scholar 

  8. Riad R, Omar W, Sidhom I, Zamzam M, Zaky I, Hafez M et al (2010) False-positive F-18 FDG uptake in PET/CT studies in pediatric patients with abdominal Burkitt’s lymphoma. Nucl Med Comm 31:232–238

    Article  Google Scholar 

  9. Karantanis D, Durski JM, Lowe VJ, Nathan MA, Mullan BP, Georgiou E et al (2012) 18F-FDG PET and PET/CT in Burkitt’s lymphoma. Eur J Radiol 75:e68–73

    Article  Google Scholar 

  10. Bailly C, Eugène T, Couec ML, Strullu M, Frampas E, Campion L et al (2014) Prognostic value and clinical impact of (18)FDG-PET in the management of children with Burkitt lymphoma after induction chemotherapy. Front Med (Lausanne) 16(1):54

    Google Scholar 

  11. Heissa KM, Allen CE, Kamdar K, Simko S, Dreyer Z, Steuber P et al (2014) Pediatric Burkitt’s lymphoma and diffuse B cell lymphoma: are surveillance scans required? Pediatr Hematol Oncol 31:253–257

    Article  Google Scholar 

  12. Carrillo-Cruz E, Mar ın-Oyaga VA, Rodrıguez MS, Borrego-Dorado I, de la Cruz Vicente F, Quiroga Cantero E et al (2015) Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma. Eur J Haematol 94:23–30

    Article  CAS  Google Scholar 

  13. Wei WX, Huang JJ, Li WY, Zhang X, Xia Y, Jiang WQ et al (2015) Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt's lymphoma. Chin J Cancer 2(34):608–613

    Google Scholar 

  14. Davidson T, Priel E, Schiby G, Raskin S, Chikman B, Nissan E et al (2018) Low rate of spleen involvement in sporadic Burkitt lymphoma at staging on PET-CT. Abdom Radiol 43:2369–2374

    Article  Google Scholar 

  15. Albano D, Bosio G, Re A, Pagani C, Giubbini R, Bertagna F (2019) Metabolic behaviour and prognostic value of early and end of treatment 18F-FDG PET/CT in adult burkitt lymphoma: role of Deauville and IHP criteria. Leuk Lymphoma 3:1–8

    Google Scholar 

  16. Albano D, Bosio G, Pagani C, Re A, Tucci A, Giubbini R et al (2019) (2019) Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma. Eur J Nucl Med Mol Imaging 46:87–96

    Article  Google Scholar 

  17. Albano D, Re A, Tucci A, Giubbini R, Bertagna F (2019) Prognostic role of ΔMTV and ΔTLG in Burkitt lymphoma. Ann Nucl Med 33:280–287

    Article  Google Scholar 

  18. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068

    Article  Google Scholar 

  19. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 32:3048–3058

    Article  Google Scholar 

  20. Albano D, Ferro P, Bosio G, Fallanca F, Re A, Tucci A et al (2019) Diagnostic and clinical impact of staging 18F-FDG PET/CT in mantle-cell lymphoma: a two-center experience. Clin Lymphoma Myeloma Leuk 19:e457–464

    Article  Google Scholar 

  21. Albano D, Laudicella R, Ferro P, Allocca M, Abenavoli E, Buschiazzo A et al (2019) The role of 18F-FDG PET/CT in staging and prognostication of mantle cell lymphoma: an italian multicentric study. Cancers (Basel) 11(12):1831

    Article  Google Scholar 

  22. Kostakoglu L, Chauvie S (2018) Metabolic tumour volume metrics in lymphoma. Semin Nucl Med 48:50–66

    Article  Google Scholar 

  23. Albano D, Bosio G, Bianchetti N, Pagani C, Re A, Tucci A et al (2019) Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma. Ann Nucl Med 33:449–458

    Article  CAS  Google Scholar 

  24. Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O et al (2014) Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 41:1735–1743

    Article  Google Scholar 

  25. Moskowitz AJ, Schoder H, Gavane S, Thoren KL, Fleisher M, Yahalom J et al (2017) Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood 130:2196–2203

    Article  CAS  Google Scholar 

  26. Albano D, Bertoli M, Battistotti M, Rodella C, Statuto M, Giubbini R et al (2018) Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma. Ann Nucl Med 32:532–541

    Article  CAS  Google Scholar 

Download references

Funding

This study did not receive any funding.

Author information

Authors and Affiliations

  1. Nuclear Medicine Department, ASST Spedali Civili Brescia, University of Brescia, Brescia, Italy

    Domenico Albano, Francesco Bertagna & Raffaele Giubbini

Authors
  1. Domenico Albano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesco Bertagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raffaele Giubbini
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Albano D: literature search, literature review, manuscript writing; Bertagna F, Giubbini R: manuscript editing, content planning.

Corresponding author

Correspondence to Domenico Albano.

Ethics declarations

Conflict of interest

All authors declare no conflict of interest related to this work.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Albano, D., Bertagna, F. & Giubbini, R. 18F-FDG PET/CT role in Burkitt lymphoma. Clin Transl Imaging 8, 39–45 (2020). https://doi.org/10.1007/s40336-020-00356-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40336-020-00356-2

Keywords

Search

Navigation